MITAORTA - Role of Mitochondrial Dynamic in Aneurysm and Dissection of Ascending Thoracic Aorta
NCT ID: NCT05434481
Last Updated: 2024-06-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
60 participants
INTERVENTIONAL
2022-09-07
2024-10-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mechanical Characterization of Ascending Aorta in Patients With and Without Aortic Dissection
NCT02860182
Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells
NCT02919709
Hemodynamic Changes in the Aorta After Endovascular Treatment of the Aortic Dissection
NCT03669055
4D Motion of the Aorta in the Chest and Simulated Wall Stress Distribution in Relation to Aortic Events
NCT04958083
Aortic Elongation and Dissection
NCT02722889
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mitochondrial fusion and fission constitute mitochondrial dynamic and are involved in the mechanisms described above.
The alteration of mitochondrial dynamics has been demonstrated in many pathologies, in particular neurological, cancer and cardiovascular disease and generally occurs in favor of fission.
In a mouse model (FASEB J, 2021, Robert P ), the role of mitochondrial fusion has been demostrated as a protective factor against hypertension in resistance arteries and a deletion of OPA1 (optic Atrophy 1) fusion protein may lead to aneurysm until aortic dissection. The results of this experimental study suggest a role of the alteration of mitochondrial dynamic in the development of aneurysm and aortic dissection.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aneurysm group
Patients operated for aneurysm of the ascending aorta according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases
* For each patient: a segment of aorta will be sampled and cutted into 4 parts
* 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.
* 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.
* 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.
* For each patient, 2 arterial blood samples will be collected before general anaesthesia
* One tube of whole blood stored at -80°C for metabolomic analysis.
* One tube of blood stored at -80°C for plasma cytokines
Type A aortic dissection group
Patients operated for type A aortic dissection according the guidelines on the diagnosis and treatment of aortic diseases (European Society of Cardiology - 2014).
Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases
* For each patient: a segment of aorta will be sampled and cutted into 4 parts
* 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.
* 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.
* 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.
* For each patient, 2 arterial blood samples will be collected before general anaesthesia
* One tube of whole blood stored at -80°C for metabolomic analysis.
* One tube of blood stored at -80°C for plasma cytokines
Control group
Patients without aortic aneurysm or aortic dissection operated for aortic valve replacement (AVR) and/or coronary artery bypass with a saphenous vein graft for proximal aortic anastomosis to collect the aortic sample. For patients operated for AVR, an aortic sample will be collected before closing the aorta.
Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases
* For each patient: a segment of aorta will be sampled and cutted into 4 parts
* 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.
* 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.
* 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.
* For each patient, 2 arterial blood samples will be collected before general anaesthesia
* One tube of whole blood stored at -80°C for metabolomic analysis.
* One tube of blood stored at -80°C for plasma cytokines
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases
* For each patient: a segment of aorta will be sampled and cutted into 4 parts
* 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network.
* 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis.
* 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis.
* For each patient, 2 arterial blood samples will be collected before general anaesthesia
* One tube of whole blood stored at -80°C for metabolomic analysis.
* One tube of blood stored at -80°C for plasma cytokines
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aortic dissection group: patients treated for type A acute aortic dissection or intramural hematoma of the ascending thoracic aorta in emergency.
* Control group: patients operated for aortic valve replacement (little aortic sample before closing aortotomy) or coronary artery bypass grafting which the use of a saphenous graft and the performance of a proximal anastomosis on the ascending aorta is planned
Exclusion Criteria
* Other acute aortic syndromes (penetrating ulcers, iatrogenic or traumatic dissections)
* Patients treated for aortic valve replacement in the context of infective endocarditis
* Patients treated for emergency aortic valve replacement or coronary bypass surgery\*\*
* Pregnant, parturient and breastfeeding women
* Patients protected by an administrative or judicial measure (curatorship, guardianship)
* Patients receiving psychiatric care under duress
* Adults subject to a legal protection measure.
* Patients whose the samples planned for the study could not be taken;
* Patients in the control group whose tissue sampling will not be performed.
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation de l'Avenir
OTHER
University Hospital, Angers
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Olivier FOUQUET
Angers, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Trabado S, Al-Salameh A, Croixmarie V, Masson P, Corruble E, Feve B, Colle R, Ripoll L, Walther B, Boursier-Neyret C, Werner E, Becquemont L, Chanson P. The human plasma-metabolome: Reference values in 800 French healthy volunteers; impact of cholesterol, gender and age. PLoS One. 2017 Mar 9;12(3):e0173615. doi: 10.1371/journal.pone.0173615. eCollection 2017.
Robert P, Nguyen PMC, Richard A, Grenier C, Chevrollier A, Munier M, Grimaud L, Proux C, Champin T, Lelievre E, Sarzi E, Vessieres E, Henni S, Prunier D, Reynier P, Lenaers G, Fassot C, Henrion D, Loufrani L. Protective role of the mitochondrial fusion protein OPA1 in hypertension. FASEB J. 2021 Jul;35(7):e21678. doi: 10.1096/fj.202000238RRR.
Toda M, Yamamoto K, Shimizu N, Obi S, Kumagaya S, Igarashi T, Kamiya A, Ando J. Differential gene responses in endothelial cells exposed to a combination of shear stress and cyclic stretch. J Biotechnol. 2008 Jan 20;133(2):239-44. doi: 10.1016/j.jbiotec.2007.08.009. Epub 2007 Aug 9.
Archer SL. Mitochondrial dynamics--mitochondrial fission and fusion in human diseases. N Engl J Med. 2013 Dec 5;369(23):2236-51. doi: 10.1056/NEJMra1215233. No abstract available.
Piquereau J, Caffin F, Novotova M, Prola A, Garnier A, Mateo P, Fortin D, Huynh le H, Nicolas V, Alavi MV, Brenner C, Ventura-Clapier R, Veksler V, Joubert F. Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload. Cardiovasc Res. 2012 Jun 1;94(3):408-17. doi: 10.1093/cvr/cvs117. Epub 2012 Mar 8.
Le Page S, Niro M, Fauconnier J, Cellier L, Tamareille S, Gharib A, Chevrollier A, Loufrani L, Grenier C, Kamel R, Sarzi E, Lacampagne A, Ovize M, Henrion D, Reynier P, Lenaers G, Mirebeau-Prunier D, Prunier F. Increase in Cardiac Ischemia-Reperfusion Injuries in Opa1+/- Mouse Model. PLoS One. 2016 Oct 10;11(10):e0164066. doi: 10.1371/journal.pone.0164066. eCollection 2016.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A00719-34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.